Drug news
Merck Serono withdraws EMA application for treatment of Non Small Cell Lung Cancer
Merck-Serono announced the strategic decision to voluntarily withdraw the marketing authorization application to the European Medicines Agency of a label extension for Erbitux (cetuximab) in combination with standard first-line platinum-based chemotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer with high epidermal growth factor receptor expression. The decision to withdraw the application was based on feedback from European regulatory authorities, indicating that further data would be required.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.